SEC Filing Analysis: Artiva Biotherapeutics, Inc. (RTVA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A company officer and director has filed a notice of a proposed sale of common stock valued at approximately $42,000. The transaction is pre-planned under a 10b5-1 plan.
• Market Impact: The transaction is of low materiality and is not expected to have a meaningful impact on the stock.

Company Information

Field	Value
Company	Artiva Biotherapeutics, Inc.
Ticker Symbol	RTVA
CIK	0001817241
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	FRED ASLAN
CIK	0001909362
Title/Position	Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-12-15 (Approximate Sale Date)
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	12,749
Price Per Share	~$3.30 (Calculated)
Total Value	$42,071.70
Shares Owned After	Not specified
Ownership Type	Not specified

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$42,071.70
% of Market Cap	0.053%
Shares Transacted	12,749
% of Shares Outstanding	0.052%
Post-Transaction Ownership	Not specified
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of $42,071.70 is negligible compared to Artiva's market capitalization of $80 million.
• Ownership Concentration: Without post-transaction ownership data, a full assessment is not possible, but the size of the sale itself is minor.
• Transaction Significance: The sale represents less than 0.1% of both the market cap and shares outstanding (24,544,904 shares), categorizing it as a low-significance event.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a small, pre-scheduled sale under a 10b5-1 plan. Such transactions are common for executive compensation and liquidity and typically do not signal a change in the insider's outlook on the company.

Volume & Sentiment

• Expected Volume Impact: Negligible. The number of shares is too small to materially affect daily trading volume.
• Sentiment Indicator: Neutral. The market generally disregards small, planned sales by insiders.

Additional Context

Transaction Notes

• Special Circumstances: The filing indicates this is a proposed sale under a Rule 10b5-1 trading plan adopted on July 23, 2024. The shares are related to the vesting of restricted stock units (RSUs).